The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Prior to publication of each Guideline, a Call for Comment phase is opened available only for SITC members to review a draft copy of the Guideline and provide feedback in the goal of further improving the draft. Click here to learn more about the Call for Comment process.
In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An update of the melanoma consensus statement and new guidelines for bladder and lung cancers are also underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.
Published August 27, 2013 in Nature Reviews Clinical Oncology as "The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma."
An update to the Melanoma Guidelines is expected to be published in 2017.
Published November 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
NOW AVAILABLE: Renal Cell Carcinoma Pocket Guide – SITC is pleased to offer a convenient and new pocket-sized summary of the society’s Cancer Immunotherapy Guidelines for renal cell carcinoma. Access key information to help implement cancer immunotherapy in your practice.
Click here to purchase your Pocket Guide.
Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."
Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."
SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating the consensus statement; therefore, each Cancer Immunotherapy Guidelines Task Force comprises a comprehensive mix of academic physicians and researchers,nurses, patients, and patient advocates invited from a diversity of institutions across the United States.
Each expert Task Force addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and then develops evidence-based recommendations by recording consensus opinions of the Task Force and documenting alternative opinions when they occur.
Members receive free access to download SITC's Cancer Immunotherapy Guidelines – Immunotherapy for Renal Cell Carcinoma Digital Pocket Guide on any desktop or mobile device through a members only link*
To receive this benefit, please sign in to your SITC member account for the link to appear on this page.
*Available only through the Guideline Central App.
Be Part of the Breakthrough at the Charles River World Congress on Animal Models in Drug Discovery & Development. Boston | September 26-27, 2017 http://breakthroughs.criver.com/index.html
Use of mAb-based immunotherapies has resulted in major improvements in treatment of B-cell neoplasms, but patients can relapse, succumbing to the disease. An alternative approach that destroys tumor cells including cancer stem cells is, thus, needed urgently. ...
According to the cited pharma company document within, out of Hemel Hempstead, England, May 10, 2017, Dinutuximab beta, originally developed by the Vienna-based biotech company Apeiron Biologics for neuroblastoma, was previously available in Europe under ...
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients. In this exclusive interview with Oncology Central, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org